"L’Istituto Oncologico della Svizzera Italiana (IOSI) raggruppa in un’unica struttura organizzativa tutte le specialità non chirurgiche che all’interno dell’Ospedale multisito EOC si occupano di tumori. Lo IOSI è basato sul modello del “Comprehensive Cancer Centre”, anche se la sua struttura è adattata alla realtà del Ticino, coprendo in modo trasversale tutto l’Ospedale multisito EOC. Lo IOSI raggruppa quindi le specialità che si occupano di diagnosi, terapia e ricerca nell’ambito delle malattie tumorali. Lo IOSI propone ai suoi pazienti un approccio olistico e la possibilità di fruire dei più recenti progressi della ricerca oncologica. Grazie a tutto ciò, lo IOSI è diventato un centro di riferimento anche al di là dei confini nazionali."

During the past decade, Istituto Oncologico della Svizzera Italiana conducted 44 clinical trials. In the 10-year time frame, 44 clinical trials started and 9 clinical trials were completed, i.e. on average, 20.5% percent of trials that started reached the finish line to date. In the past 5 years, 19 clinical trials started and 5 clinical trials were completed. i.e. 26.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Istituto Oncologico della Svizzera Italiana" #1 sponsor was "Swiss Group for Clinical Cancer Research" with 53 trials, followed by "ETOP IBCSG Partners Foundation" with 8 trials sponsored, "International Extranodal Lymphoma Study Group (IELSG)" with 7 trials sponsored, "Southern Europe New Drug Organization" with 4 trials sponsored and "Stichting Hemato-Oncologie voor Volwassenen Nederland" with 4 trials sponsored. Other sponsors include 18 different institutions and companies that sponsored additional 24 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Istituto Oncologico della Svizzera Italiana" #1 collaborator was "Breast International Group" with 4 trials as a collaborator, "Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG)" with 2 trials as a collaborator, "European Organisation for Research and Treatment of Cancer - EORTC" with 2 trials as a collaborator, "Novartis" with 2 trials as a collaborator and "University Hospital, Basel, Switzerland" with 2 trials as a collaborator. Other collaborators include 50 different institutions and companies that were collaborators in the rest 59 trials.

According to Clinical.Site data, the most researched conditions in "Istituto Oncologico della Svizzera Italiana" are "Breast Cancer" (10 trials), "Prostate Cancer" (8 trials), "Advanced Solid Tumors" (7 trials), "Lymphoma" (7 trials) and "Lung Cancer" (6 trials). Many other conditions were trialed in "Istituto Oncologico della Svizzera Italiana" in a lesser frequency.

Most popular intervention types in "Istituto Oncologico della Svizzera Italiana" are "Drug" (79 trials), "Radiation" (12 trials), "Biological" (9 trials), "Other" (8 trials) and "Procedure" (7 trials). Other intervention types were less common.

The name of intervention was led by "rituximab" (5 trials), "Carboplatin" (4 trials), "Paclitaxel" (4 trials), "Placebo" (4 trials) and "Bevacizumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Istituto Oncologico della Svizzera Italiana" are 74 trials for "All" genders, 14 trials for "Female" genders and 11 trials for "Male" genders.

Currently, there are NaN active trials in "Istituto Oncologico della Svizzera Italiana". undefined are not yet recruiting, 16 are recruiting, 20 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 44 completed trials in Istituto Oncologico della Svizzera Italiana, 2 suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Istituto Oncologico della Svizzera Italiana, 20 "Phase 1" clinical trials were conducted, 45 "Phase 2" clinical trials and 28 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 8 trials that are defined as “Not Applicable".